Find clinical trials for Breast Cancer in Detroit, MI
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Breast Cancer trials near Detroit, MI, USA:
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Phase 1
Detroit, Michigan, United States and 4 other locations
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer...
Phase 1
Ann Arbor, Michigan, United States and 8 other locations
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Ann Arbor, Michigan, United States and 117 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Detroit, Michigan, United States and 226 other locations
positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. Th...
Phase 1
Detroit, Michigan, United States and 64 other locations
ARV-471 (PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combinat ...
Phase 3
Ann Arbor, Michigan, United States and 40 other locations
body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer...
Phase 2
Detroit, Michigan, United States and 9 other locations
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 a ...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 15 other locations
mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatmen...
Phase 3
Detroit, Michigan, United States and 103 other locations
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), ph...
Phase 1
Detroit, Michigan, United States and 23 other locations
Clinical trials
Research sites
Resources
Legal